Detalles de la búsqueda
1.
A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies.
Invest New Drugs
; 41(2): 317-323, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36897458
2.
Tracking medical student emotionality in relation to whole body dissection and donation.
Clin Anat
; 34(1): 128-142, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32889750
3.
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors.
Invest New Drugs
; 38(1): 120-130, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30887250
4.
Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
Br J Clin Pharmacol
; 85(6): 1239-1246, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30628113
5.
Sharing personal information about anatomical body donors: What first-year medical students want to know and how it affects emotional responses to dissection.
Clin Anat
; 32(8): 1019-1032, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31012152
6.
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
Br J Cancer
; 118(2): 153-161, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28949957
7.
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
Br J Cancer
; 118(2): e3, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29361630
8.
Correction to: A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies.
Invest New Drugs
; 41(3): 539, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37166739
9.
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
Invest New Drugs
; 36(4): 629-637, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29196957
10.
Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population.
Magn Reson Med
; 77(2): 814-825, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26918893
11.
A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.
Invest New Drugs
; 35(2): 189-197, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28111727
12.
Potential Association Between Physician Burnout Rates and Operating Margins: Specialty-Specific Analysis.
J Med Pract Manage
; 32(4): 233-238, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29969540
13.
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
Invest New Drugs
; 34(5): 604-13, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27424159
14.
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
Cancer
; 121(9): 1405-13, 2015 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25641662
15.
Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Int J Clin Pharmacol Ther
; 53(7): 563-72, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26073352
16.
Endoglin for targeted cancer treatment.
Curr Oncol Rep
; 16(2): 365, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24445497
17.
The Potential of Real-Time Behavior and Well-Being Assessments to Improve Medical Student Wellness.
Acad Med
; 99(6): 608-612, 2024 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38266202
18.
Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET.
Invest New Drugs
; 31(2): 363-9, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22547164
19.
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.
Invest New Drugs
; 31(3): 714-23, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23054206
20.
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.
BMC Cancer
; 13: 152, 2013 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-23530663